A provider may monitor: Symptoms and side effects Injection-site reactions Sleep quality Appetite changes Fluid retention Blood pressure Glucose or A1C when appropriate IGF-1 when appropriate Recovery response Whether treatment should continue, pause, or change Monitoring helps prevent patients from guessing, overusing, or continuing therapy when symptoms suggest the plan should be adjusted
Im pretty sure the pharma companies are working on this - there are already likely to be a bunch of celebrities who are on various GLP-1 formulations, and its only a matter of time they come to endorse the drugs they have used
Neurocutaneous melanosis
Ideal for athletes and fitness enthusiasts looking to optimise their energy metabolism
With less focus on cravings, you can better stick to healthy eating habits
Retatrutide delivers an average 24.2% body weight reduction over 48 weeks through its triple-agonist mechanism targeting GLP-1, GIP, and glucagon receptors